XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)        
Net Revenue $ 5,823,942 $ 4,306,324 $ 17,110,511 $ 10,797,838
Cost of goods sold 517,611 447,935 1,528,449 1,126,798
Gross profit 5,306,331 3,858,389 15,582,062 9,671,040
Operating expenses        
Selling, general and administrative expenses 6,920,105 5,072,402 18,891,979 13,632,967
Research and development 35,674 11,022 257,867 11,022
Depreciation and amortization 204,570 81,880 395,968 209,606
Total operating expenses 7,160,349 5,165,304 19,545,814 13,853,595
Operating loss (1,854,018) (1,306,915) (3,963,752) (4,182,555)
Other income (expense)        
Other income 0 100,250 0 14,776
Interest expense 0 (1,458) (711) (10,913)
Share of losses from equity method investment (193,843) 0 (472,747) 0
Total other income (expense) (193,843) 98,792 (473,458) 3,863
Net loss (2,047,861) (1,208,123) (4,437,210) (4,178,692)
Less: Net loss attributable to noncontrolling interest (27,491) (60,897) (63,604) (68,745)
Net loss attributable to Sanara MedTech common shareholders $ (2,020,370) $ (1,147,226) $ (4,373,606) $ (4,109,947)
Net loss per share of common stock, basic and diluted $ (0.27) $ (0.18) $ (0.60) $ (0.72)
Weighted average number of common shares outstanding, basic and diluted 7,518,165 6,230,648 7,279,708 5,730,554